Israel offers advanced multiple myeloma treatments including in-house developed CAR T-cell therapy, bispecific antibodies, and complex stem cell transplants. Facilities like Sheba Medical Center and Hadassah provide personalized precision medicine. These programs utilize genetic profiling to tailor targeted drug protocols for refractory cases.
- Cellular therapy: Sheba Medical Center engineers CAR-T cells on-site in 10–11 days.
- Novel immunotherapy: Clinics utilize bispecific antibodies like Teclistamab and Talquetamab for relapsed patients.
- Advanced transplantation: Specialists perform autologous, allogeneic, and tandem transplants for high-risk myeloma.
- Surgeon expertise: Dr. Abraham Avigdor at Sheba has over 35 years of oncology experience.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba are unique because they perform both pediatric and adult bone marrow transplants at massive scale. Dr. Fredi Aviv has practiced at Sourasky for over 30 years, while Sheba serves nearly 2 million patients annually. This high volume allows doctors to manage complex side effects from aggressive daratumumab combinations more effectively than smaller regional centers.
Patient Consensus: Patients note that access to tandem transplants is often faster in Israel than in the US. Many suggest prioritizing bispecific antibodies over CAR-T if you have limited mobility, as the administration process is simpler.
